Your browser is no longer supported. Please, upgrade your browser.
PFE Pfizer Inc. daily Stock Chart
Pfizer Inc.
IndexDJIA S&P500 P/E24.14 EPS (ttm)1.37 Insider Own0.04% Shs Outstand6.01B Perf Week-0.69%
Market Cap199.10B Forward P/E12.04 EPS next Y2.75 Insider Trans-11.09% Shs Float5.92B Perf Month-0.51%
Income8.35B PEG4.30 EPS next Q0.64 Inst Own70.70% Short Float0.73% Perf Quarter3.14%
Sales52.35B P/S3.80 EPS this Y5.20% Inst Trans-1.04% Short Ratio2.36 Perf Half Y-1.31%
Book/sh9.79 P/B3.39 EPS next Y7.54% ROA4.90% Target Price37.45 Perf Year-4.85%
Cash/sh2.39 P/C13.89 EPS next 5Y5.62% ROE14.00% 52W Range29.83 - 35.38 Perf YTD2.06%
Dividend1.28 P/FCF13.09 EPS past 5Y3.30% ROI7.80% 52W High-6.30% Beta0.98
Dividend %3.86% Quick Ratio1.10 Sales past 5Y-2.80% Gross Margin78.20% 52W Low11.13% ATR0.38
Employees96500 Current Ratio1.30 Sales Q/Q-1.90% Oper. Margin20.80% RSI (14)46.59 Volatility1.30% 1.18%
OptionableYes Debt/Eq0.75 EPS Q/Q52.90% Profit Margin16.00% Rel Volume0.73 Prev Close32.76
ShortableYes LT Debt/Eq0.59 EarningsAug 01 BMO Payout88.90% Avg Volume18.27M Price33.15
Recom2.50 SMA20-0.08% SMA50-0.51% SMA2000.53% Volume13,452,221 Change1.19%
Jul-20-17Downgrade Credit Suisse Outperform → Neutral
May-16-17Downgrade Citigroup Neutral → Sell
Dec-02-16Initiated Guggenheim Neutral
Nov-02-16Downgrade Argus Buy → Hold
Oct-13-16Downgrade Jefferies Buy → Hold
Jun-20-16Reiterated Jefferies Buy $42 → $40
May-12-16Initiated Berenberg Hold $38
May-04-16Reiterated UBS Buy $36 → $38
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Apr-07-16Resumed JP Morgan Overweight $38
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Jun-17-15Initiated Piper Jaffray Overweight
Apr-30-15Reiterated Argus Buy $36 → $39
Apr-29-15Downgrade Citigroup Buy → Neutral
Jan-28-15Reiterated Argus Buy $35 → $36
Aug-23-17 02:21AM  India grants Pfizer patent on pneumonia vaccine in blow to aid group Reuters
Aug-22-17 03:47PM  What's Next for Bristol-Myers Squibb After Its Opdivo Setback? Motley Fool
10:44AM  Immunomedics' Progress in Phase II Cancer Study Encouraging Zacks
09:47AM  India grants Pfizer patent on pneumonia vaccine in blow to aid group Reuters
09:07AM  How Allergans US Specialized Therapeutics Segment Performed in 2Q17 Market Realist
08:00AM  Alliance Foundation Trials Opens Global Trial Investigating First-in-Class Palbociclib in HR+, HER2+ Metastatic Breast Cancer Business Wire
07:33AM  India grants Pfizer patent on pneumonia vaccine in blow to aid group Reuters
06:30AM  3 High-Yield Pharmaceutical Stocks Motley Fool
Aug-21-17 07:46PM  3 Dividend Stocks Perfect for Retirement Motley Fool
10:37AM  Pfizer Inc. :PFE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 21, 2017 Capital Cube
08:21AM  Better Buy: AbbVie Inc. vs. Pfizer Inc. Motley Fool
Aug-20-17 08:15AM  Pfizer's Besponsa Is Yet Another Win for the Biopharma Giant Motley Fool
07:43AM  Here's How Much $10,000 Invested in Pfizer in 1977 Is Worth Now Motley Fool
Aug-19-17 01:01AM  [$$] Healthy Dividends
Aug-18-17 11:35AM  The FDA Just Approved a New Pfizer Cancer Drug for a Rare, Vicious Leukemia Fortune
09:18AM  Pfizer's (PFE) Besponsa Gets FDA Nod with a Boxed Warning Zacks
08:00AM  See what the IHS Markit Score report has to say about Pfizer Inc. Markit
07:45AM  The Zacks Analyst Blog Highlights: Pfizer, TJX Companies, Honda, American Electric and Novo Nordisk Zacks
07:39AM  Analysts Recommendations for Bristol-Myers Squibb in August 2017 Market Realist
07:09AM  Pharma Stock Roundup: Multiple Sclerosis Drug Prices in Focus, Mixed Data on BMY's Opdivo Zacks
06:59AM  Bristol-Myers Squibb and Pfizer to Highlight Commitment to Reducing the Risk of Stroke Caused by Non-Valvular Atrial Fibrillation (NVAF) and Treating Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE) at ESC Congress 2017 Business Wire
Aug-17-17 05:42PM  Top Analyst Reports for Pfizer, TJX Companies & Honda Zacks
05:36PM  FDA OKs Pfizer drug for rare, fast-killing type of leukemia Associated Press
03:59PM  FDA approves Pfizer's drug for rare blood cancer Reuters
01:57PM  Pfizer Receives U.S. FDA Approval for BESPONSA® (inotuzumab ozogamicin) Business Wire
01:48PM  FDA approves Pfizer's drug for rare blood cancer Reuters
10:06AM  Can Pfizer Bank on New Immunotherapy Bavencio for Growth? Zacks
07:36AM  How Amgens Nephrology Drugs Are Positioned after 2Q17? Market Realist
Aug-16-17 10:16AM  The Bull Case for Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Weak InvestorPlace
Aug-15-17 10:36AM  Pfizers Corporate and Pipeline Developments in 2Q17 Market Realist
09:13AM  Pfizer Inc. breached its 50 day moving average in a Bullish Manner : PFE-US : August 15, 2017 Capital Cube
09:06AM  Pfizers Important Product Developments in 2Q17 Market Realist
08:00AM  See what the IHS Markit Score report has to say about Pfizer Inc. Markit
07:36AM  Pfizers Declining-Revenue Products in 2Q17 Market Realist
05:00AM  Whats Harder Than Making Copycat Biotech Drugs? Selling Them Bloomberg
Aug-14-17 10:37AM  Pfizers Major Growth Drivers in 2Q17 Market Realist
09:07AM  Understanding Pfizers Geographical Performance in 2Q17 Market Realist
08:00AM  See what the IHS Markit Score report has to say about Pfizer Inc. Markit
07:37AM  Pfizers Innovative and Essential Health Businesses in 2Q17 Market Realist
Aug-13-17 02:03PM  Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions? Motley Fool
Aug-12-17 12:13PM  Video games could soon replace pills in treating Alzheimer's disease and depression CNBC
08:00AM  See what the IHS Markit Score report has to say about Pfizer Inc. Markit
Aug-11-17 09:36PM  Edited Transcript of PFE earnings conference call or presentation 1-Aug-17 2:00pm GMT Thomson Reuters StreetEvents
08:26PM  Pfizer Inc. Value Analysis (NYSE:PFE) : August 12, 2017 Capital Cube
05:35PM  Pfizers 2Q17 Earnings: What You Need to Know Market Realist
03:59PM  Pfizers Valuation after 2Q17 Earnings Market Realist
11:46AM  On earnings calls, corporate leaders openly bemoan DC's lack of direction CNBC
09:06AM  Luspatercept: Opportunity for Celgenes Long-Term Growth? Market Realist
08:00AM  IHS Markit Score Update: Rise in demand for ETFs holding Pfizer Inc is a positive for its shares Markit
01:51AM  Pfizer Alum's China Startup Is Said to Select Banks for IPO Bloomberg
Aug-10-17 08:18PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfizer Inc. - PFE PR Newswire
07:36PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfizer Inc. - PFE PR Newswire
09:15AM  3 High-Yield Healthcare Stocks Motley Fool
08:40AM  Short Sellers Hike Bets in Major Pharma 24/7 Wall St.
Aug-09-17 01:02PM  Analysts Recommendations for Celgene in August 2017 Market Realist
11:47AM  Mexico watchdog finds big pharma faces no competition on some drugs Reuters
07:00AM  Earnings Review and Free Research Report: Johnson Controls Adjusted Net Income Soared 69.4% ACCESSWIRE
Aug-08-17 09:00PM  Why Vertex Pharmaceuticals Incorporated (VRTX) Will Keep Rolling Higher InvestorPlace
06:06PM  [$$] Aclaris Therapeutics Buys Confluence Life Sciences in $100 Million Deal The Wall Street Journal
12:37PM  Why Martin Shkreli Wont Be the Last Pharma Bro Fortune
08:45AM  Pfizer investing $100M in Sanford plant expansion, adding jobs American City Business Journals
Aug-07-17 12:13PM  Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire
09:59AM  The Zacks Analyst Blog Highlights: Apple, Pfizer, Intel, Chevron and Exxon Mobil Zacks
09:45AM  Q2 Earnings Fail to Impress Pharma ETF Zacks
Aug-05-17 11:52AM  Earnings Preview: What To Expect From Valeant Pharmaceuticals On Tuesday Forbes
Aug-04-17 04:45PM  Dow 30 Stock Roundup: Apple Impresses, Pfizer Beats on Earnings Zacks
11:13AM  [$$] CVS Formulary Changes Boost JNJ, Pfizer; Hurt Lilly
10:55AM  Dow Jones Reaches Another New High, Closes at 22,026.10
08:47AM  Pharma Stock Roundup: Mixed 2Q Results from Pfizer, Bristol-Myers Announces IO Deals Zacks
Aug-03-17 11:39PM  Asian stocks mixed as US jobs, politics in focus Associated Press
05:19PM  Dow bags 7th straight record, but energy slump weighs on broader stock market MarketWatch
05:04PM  Momenta (MNTA) Q2 Loss In Line with Estimates, Sales Beat Zacks
02:10PM  FDA Advisory Committee Votes in Favor of XELJANZ® (tofacitinib citrate) for the Treatment of Active Psoriatic Arthritis Business Wire
08:00AM  Today's Research Reports on Stocks to Watch: Pfizer and Procter & Gamble ACCESSWIRE
Aug-02-17 11:15AM  A Large-Scale Acquisition Is Unlikely for Pfizer Until This Happens Motley Fool
10:09AM  Company News For August 02, 2017 Zacks
10:05AM  With 22K in the books, here are the stocks Wall Street believes will lead the Dow to 23,000 CNBC
10:00AM  Pfizer Stock Upgraded at BMO on Attractive Risk/Reward, Growth Outlook
09:08AM  Pfizer upgraded to outperform at BMO Capital Markets on drug pipeline progress MarketWatch
08:00AM  Earnings Preview: What To Expect From Regeneron Pharmaceuticals On Thursday Forbes
07:37AM  How BMY Is Valued following Its 2Q17 Earnings Market Realist
07:35AM  Eli Lillys Valuation after 2Q17 Earnings Release Market Realist
Aug-01-17 09:33PM  Pfizer tops 2Q profit forecasts Associated Press
08:00PM  Dow Enters August With a Bang, New Records for Day Five
07:30PM  How Snap May Have Dashed Uber's IPO Hopes; Intel CEO on Autonomy, Tech Rally -- ICYMI Tuesday
04:30PM  Pfizer's Weak Viagra, Consumer Sales Drag Down Massive Gains in New Products
04:22PM  Will Pfizer's Cancer Drugs Help It Grow Without A Merger? Investor's Business Daily
04:11PM  Generics Chip Away At Dow Stock Pfizer, But Cancer Unit 'Stabilizing' Investor's Business Daily
03:02PM  12 Numbers in Pfizer's Q2 Update More Important Than Its Revenue Decline Motley Fool
02:32PM  Pfizer's New Tax Obsession Shouldn't Paralyze It Bloomberg
02:15PM  Dow on Track for Fifth Record Close in a Row, Wall Street Rises
01:36PM  Pfizer delays major M&A as it awaits U.S. tax reform clarity Reuters
01:33PM  Pfizer Remains Underappreciated Morningstar
01:26PM  Big movers in the blitz CNBC Videos
01:19PM  [$$] Pfizer Waiting for Cues on Tax Reform to Pursue Deals The Wall Street Journal
12:38PM  [$$] Pfizer hits pause on deals amid US tax reform uncertainty Financial Times
12:13PM  Why Garmin Ltd. (GRMN) Stock Should Still Be Avoided InvestorPlace
11:54AM  The 8 'Dogs Of The Dow' Gained Ground On The Dow 30 Forbes
11:25AM  Q2 Earnings From UA, PFE And ADM Zacks
11:00AM  Pfizer Looks Undervalued Morningstar
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Viagra, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that will lose or have lost marketing patent protection; branded generic products; sterile injectable products; biosimilars; and infusion systems. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, and Pristiq brand names. This segment also engages in contract manufacturing business. The company has licensing agreements with Cellectis SA and AstraZeneca plc; and collaborative agreements with Eli Lilly & Company and Merck KGaA. It also has a research collaboration and license agreement with HitGen Ltd. to build and screen DNA-encoded libraries in order to discover small molecule leads to be used in drug development; collaboration with Merck and Corning for pharma glass packaging project; and an agreement with InSphero AG to develop a predictive toxicology assay using InSphero 3D InSight human liver microtissues for predicting drug induced liver injury. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MACKENZIE ALEXANDER RExecutive Vice PresidentAug 07Sale33.5015,000502,560139,474Aug 09 05:00 PM
READ IAN CChairman & CEOAug 04Sale34.0068,8342,340,356221,955Aug 08 05:02 PM
READ IAN CChairman & CEOAug 04Sale34.0028,116955,944636,293Aug 08 05:02 PM
JOHNSON RADY AExecutive Vice PresidentMar 10Sale34.194,500153,85554,963Mar 13 05:36 PM
HILL CHARLES HExecutive Vice PresidentMar 09Sale34.0736,0001,226,52057,329Mar 10 03:59 PM
LANKLER DOUGLAS MExecutive Vice PresidentMar 02Sale34.6620,000693,20083,793Mar 03 04:06 PM
Dolsten MikaelPresident R&DMar 02Sale34.5515,401532,10549,318Mar 03 04:06 PM
Dolsten MikaelPresident R&DMar 01Sale34.4815,569536,81964,719Mar 03 04:06 PM
Dolsten MikaelPresident R&DFeb 27Sale34.2658,8462,016,24480,288Mar 01 05:10 PM
JOHNSON RADY AExecutive Vice PresidentFeb 23Option Exercise21.0321,238446,63572,172Feb 27 06:30 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 23Option Exercise21.03103,1552,169,350295,356Feb 27 06:30 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 23Option Exercise21.0351,5781,084,685138,758Feb 27 06:30 PM
LUND-JURGENSEN KIRSTENExecutive Vice PresidentFeb 23Option Exercise21.0321,238446,63533,848Feb 27 06:30 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 23Option Exercise21.03218,4474,593,940592,765Feb 27 06:21 PM
BOURLA ALBERTGroup PresidentFeb 23Option Exercise21.0342,476893,270165,474Feb 27 06:21 PM
Dolsten MikaelPresident R&DFeb 23Option Exercise21.03218,4474,593,940299,915Feb 27 06:21 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 23Option Exercise21.0336,408765,660102,611Feb 27 06:10 PM
READ IAN CChairman & CEOFeb 23Option Exercise21.03788,83516,589,2001,124,093Feb 27 06:55 PM
SUSMAN SALLYExecutive Vice PresidentFeb 23Option Exercise21.03115,2912,424,570247,765Feb 27 06:55 PM
YOUNG JOHN DGroup PresidentFeb 23Option Exercise21.0351,5781,084,685172,542Feb 27 06:56 PM
OLSON LAURIE JExecutive Vice PresidentFeb 23Option Exercise21.0327,306574,24599,224Feb 27 06:47 PM
MACKENZIE ALEXANDER RExecutive Vice PresidentDec 07Option Exercise25.8730,000776,100167,687Dec 08 09:48 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 09Sale33.0010,000330,000112,087Nov 10 07:44 PM
BOURLA ALBERTGroup PresidentNov 04Option Exercise24.9920,000499,800149,199Nov 07 05:58 PM
BOURLA ALBERTGroup PresidentNov 04Sale30.0518,390552,530130,809Nov 07 05:58 PM
HILL CHARLES HExecutive Vice PresidentNov 03Option Exercise21.0353,9181,133,896115,033Nov 07 05:50 PM
MADDALUNA ANTHONY JExecutive Vice PresidentNov 02Option Exercise21.0332,545684,421122,087Nov 04 04:36 PM